Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used in SpectraCure's ongoing clinical study. The technology leads to increased precision, accuracy and safety in the treatment of recurrent prostate cancer.SpectraCure runs an EU-funded development project, together with MedCom GmbH. The purpose of the project is to adapt MedCom's medical imaging technology to SpectraCure's IDOSE treatment planning system, thereby improving IDOSE® and make it more effective. The project has now reached a point where MedCom's system will